OncoResponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of Elite Cancer Responders.
OncoResponse utilizes a clinically validated Technology Platform to discover authentic human antibodies to multiple high value targets associated with immunosuppressive myeloid biology.
OncoResponse was founded in 2016 by Clifford Stocks. The company is headquartered in Seattle, Washington.
OncoResponse, with a broad strategic alliance with MD Anderson Cancer Center, deploys a proprietary B-cell discovery platform to identify and develop novel antibodies targeting immune cells in the tumor microenvironment.
OncoResponse's lead clinical candidate, OR2805 is a fully human antibody discovered using B cells derived from an Elite Responder to checkpoint inhibitor (CPI) therapy. OR2805 has entered cohort expansion trials in multiple cancer indications.
OncoResponse's additional pipeline candidates that modulate suppressive macrophage activity are under development, include OR502, a best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression.
OncoResponse is backed by RiverVest Venture Partners, Qatar Investment Authority (QIA), CPRIT, ARCH Venture Partners, Canaan Partners, Bering Capital, Takeda Ventures, InterVest, 3B Future Health Fund, Magnetar Group, Yonjin Venture, and others. The company raised $27M in new financing, consisting of a $13M in grant and a $14M in equity round on May 18, 2023. This brings OncoResponse's total funding to $130.1M to date.